
Shares of Regencell Bioscience (NASDAQ:RGC) gained 49,637% in the past six months despite record losses since going public in 2021. The Chinese medicine company, with shareholders like Digital Mobile Venture, BlackRock, Morgan Stanley, and RBC, went public in 2021. It develops herbal medicine treatments for neurocognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD).
The company posted over £7.4 million ($10 million) in losses in the past two fiscal years. Despite being unprofitable, RGC shares made monumental moves on no major developments or company news, leaving investors confused about investment prospects.